India's CNBC-TV18 examines implications of country's decision to issue compulsory license for Bayer cancer drug

"India's grant of a compulsory license to Natco for Bayer's kidney-cancer drug Nexavar has sent shockwaves across the globe," but "India has found a backer in the World Health Organization," CNBC-TV18's "moneycontrol.com" reports. "India has taken a good political stand on compulsory license and we respect that move. India is a lead supplier of cheaper generics and this compulsory license will further strengthen it," Nata Menabde a representative for the WHO in India, said, according to the news service. In a video report titled "License to Cure," reporter Archana Shukla interviews a number of experts regarding the global implications of the decision (8/17).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Blood test may help identify risk of bladder cancer recurrence after surgery